Delving into the Latest Updates on ARA Healthcare Pvt. Ltd. with Synapse

Overview

Tags

Neoplasms

Immune System Diseases

Digestive System Disorders

Biosimilar

Single-chain FV antibody fragment

Recombinant protein

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2
Immune System Diseases	1
Infectious Diseases	1
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Biosimilar	2
Single-chain FV antibody fragment	1
Peptide drug conjugates	1
Recombinant protein	1

Top 5 Target	Count

IFN α(interferon alpha)	1

To evaluate the bioavailability of exemestane (EXM) from self-micro emulsifying drug delivery systems (SMEDDS) and suspension formulations, a sensitive, specific, and rapid liquid chromatog.-mass spectrometric method was developed and validated.The analyte was extracted from plasma samples and detected by mass spectrometry (MS) with an atm. pressure pos.-ion chem. ionization (APCI) mode using a heated nebulizer interface.Progesterone (PGS) was used as the internal standardA Hychrome RPB-L428 column was used to perform the chromatog. separation, the mobile phase being methanol and 15 mM ammonium formate (80:20).The MS detection used a heated nebulizer interface, with multiple reaction monitoring (MRM) operated in pos.-ion mode.Both, EXM and PGS were well-separated and identified by their relative retention times, i.e., 1.13 and 1.84 min, resp.After oral administration of EXM loaded SMEDDS and suspension formulation to rats, a significant difference was observed in the pharmacokinetic behavior of drug in both the formulations, and a 2.9-fold increase in the relative bioavailability of EXM was observed with the SMEDDS as compared with suspension formulation.The developed method was found to be suitable for bioanal. of exemestane and, hence, successfully depicted the bioavailability enhancement of exemestane SMEDDS in Wistar rats.

100 Deals associated with ARA Healthcare Pvt. Ltd.

Login to view more data

100 Translational Medicine associated with ARA Healthcare Pvt. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ARA-8	Inflammation More	Preclinical
ARABS-1	Acute Lymphoblastic Leukemia More	Preclinical
ARA-1	Neoplasms More	Preclinical
ARABS-4 ( IFN α )	Hepatitis C More	Preclinical
ARA-3	Neoplasms More	Pending